Elsa Renee Flores

Moffitt Cancer Center ACD & Division Chief, Basic Science. Cancer Biologist. Discovery Science.

[Moffitt Cancer Center @MoffittNews]

From the Moffitt booth at #AACR26, insights from Elsa Flores, PhD (@LabElsaFlores), and Brian Ruffell, PhD (@Ruffell_Lab), on how tumor cells may evade immune recognition through surface molecules, particularly in genomically unstable breast cancers. #MoffittAACR26 @AACR

[Moffitt Cancer Center @MoffittNews]

From the floor at #AACR26, a conversation between Elsa Flores, PhD (@LabElsaFlores), and Chang Jiang, PhD (@ChangJiangLab), on how cancer metabolism research, including dendritic cell metabolism, may enhance immune responses and improve therapies like CAR T-cell treatment. #MoffittAACR26 @AACR

[Moffitt Cancer Center @MoffittNews]

While at #AACR26, Elsa Flores, PhD (@LabElsaFlores), and Florian Karreth, PhD (@KarrethLab), took some time to discuss how non-genetic events drive melanoma progression and how new rapid preclinical models are helping accelerate cancer research. #MoffittAACR26 @AACR

[Moffitt Cancer Center @MoffittNews]

Earlier at #AACR26, Elsa Flores, PhD (@LabElsaFlores), and Andrii Monastyrskyi, PhD, took a moment to discuss how emerging drug discovery approaches, including protein degradation and AI-driven design, are advancing new cancer therapies. #MoffittAACR26 @AACR

[Elsa Renee Flores @LabElsaFlores]

@PatrickHwuMD @MoffittNews @KarrethLab @JenBinning Thank you for coming to our labs and talking to everyone about their research. It was an inspiring morning!

[Elsa Renee Flores @LabElsaFlores]

@lab_gomes @MoffittNews Congratulations!!🍾

[Elsa Renee Flores @LabElsaFlores]

Had a memorable and exciting day celebrating Moffitt Cancer Center and the Moffitt Discovery and Innovation Center! Thank you to @TsoiKobus and @WhitingTurner !! @MoffittNews @Timadams2023 @PatrickHwuMD @HLeeMoffitt1

[Elsa Renee Flores @LabElsaFlores]

@NCIDirector @Olympics Congratulations!!

[Laura Attardi @AttardiLaura]

Thrilled to share our deconstruction of a p53 therapeutic response in #LUAD- a step toward drugging #undruggable #p53! Thanks to our amazing team! @wmx162005 @alyssamkaiser @kbieging @LabElsaFlores @MikeOzawa @MLadanyi @arati_rajeevan @rajnitin @simone_alma

[Elsa Renee Flores @LabElsaFlores]

This morning, I was thrilled to show off the progress on the Moffitt Discovery and Innovation Center at SPEROS. I can’t wait to make new discoveries with my colleagues using trans disciplinary approaches. Big thank you to @PatrickHwuMD @HLeeMoffitt1 @john Cleveland for the opportunity to lead this effort! @MoffittNews

[AACR @AACR]

James V. DeGregori, Emilia Lim, William Hill, and Kenneth Y. Tsai discussed "Early Events and Clonal Origins" in a plenary session at the AACR Special Conference on Cancer Evolution.
#AACRevol25 @LimEmilia @DrWilliamHill @KYTsaiLab

[Elsa Renee Flores @LabElsaFlores]

A pioneer and an inspiration!

In Conversation with Robert S. Langer | ACS Nano Medicine https://t.co/y8wCZ9HGsr

[Elsa Renee Flores @LabElsaFlores]

Great day at Miles for Moffitt with my team Research Rangers and my daughter, Athena! @MoffittNews @PatrickHwuMD @HLeeMoffitt1

[Moffitt Cancer Center @MoffittNews]

At #SITC25, Kenneth Tsai, MD (@KYTsaiLab), presents Phase II results showing a 57.7% pCR with neoadjuvant lenvatinib plus pembrolizumab in stage II–IV Merkel cell carcinoma. Responders show interferon and ANGPTL1 signaling; nonresponders show neural and E2F/MYC pathways with higher baseline Tregs. #MoffittSITC25

[Elsa Renee Flores @LabElsaFlores]

Highlights from the Jaeger Lab at SITC!

[Moffitt Cancer Center @MoffittNews]

Tomorrow at #SITC25, Christopher Polera will share research on how RAS inhibition reshapes the tumor immunopeptidome to reveal new immunogenic targets and inform combination immunotherapy strategies.

#MoffittSITC25 @sitcancer

[Elsa Renee Flores @LabElsaFlores]

Great Moffitt basic science at SITC!

[Moffitt Cancer Center @MoffittNews]

At #SITC25, Alex Jaeger, PhD joins Greg Sawyer, PhD (@ProfGregSawyer) to discuss the work his lab is presenting, including the immunopeptidome, MHC-I and MHC-II. #MoffittSITC25

[Moffitt Cancer Center @MoffittNews]

Live from #SITC25: Kenneth Tsai, MD (@KYTsaiLab) presents data showing that Pembrolizumab plus Levatinib demonstrated encouraging efficacy as neoadjuvant therapy for resectable clinical stage II-IV Merkel cell carcinoma.

[Moffitt Cancer Center @MoffittNews]

Tomorrow at #SITC25: Kenneth Tsai, MD, PhD (@KYTsaiLab) presents a late-breaking abstract on the molecular and immunologic correlates of response in the phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.

#MoffittSITC25 @sitcancer

[Elsa Renee Flores @LabElsaFlores]

Exciting application of bioengineering! Congratulations, @RanaFalahat @DrJamesMule!

@MoffittNews

[Rana Falahat @RanaFalahat]

Excited to share our new paper in @PNAS!
We developed biodegradable biomaterials that organize immune cells into tertiary lymphoid–like structures, potentially improving outcomes for patients less responsive to immunotherapies.
@DrJamesMule @MoffittNews
https://t.co/UVVjspTJml